CMPX Compass Therapeutics Forecast, Technical & Fundamental Analysis
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases... Show more
CMPX is expected to report earnings to rise 11.40% to -11 cents per share on August 05
Q2'26
Est.
$-0.11
Q1'26
Est.
$-0.10
Q4'25
Beat
by $0.01
Q3'25
Beat
by $0.06
Q2'25
Missed
by $0.02
The last earnings report on May 05 showed earnings per share of -10 cents, meeting the estimate of -10 cents. With 1.58M shares outstanding, the current market capitalization sits at 408.80M.
A.I.dvisor indicates that over the last year, CMPX has been loosely correlated with VCYT. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CMPX jumps, then VCYT could also see price increases.
Aroon Indicator for CMPX shows an upward move is likely
CMPX's Aroon Indicator triggered a bullish signal on June 09, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 188 similar instances where the Aroon Indicator showed a similar pattern. In of the 188 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 25, 2026. You may want to consider a long position or call options on CMPX as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
CMPX moved above its 50-day moving average on July 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CMPX advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMPX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CMPX broke above its upper Bollinger Band on July 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.028) is normal, around the industry mean (21.001). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). CMPX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (555.556) is also within normal values, averaging (368.009).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CMPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
